On December 18, 2025, Werewolf Therapeutics, Inc. (NASDAQ:HOWL) shared a comprehensive pipeline update in which it highlighted clinical progress and 2026 priorities for its INDUKINE programs and ...
Matthew Galea is a features writer for CBR. He spends his day as a high school English teacher, and every other minute watching, thinking and writing about movies and television. From Lon Chaney Jr.'s ...
The average one-year price target for Werewolf Therapeutics (NasdaqGS:HOWL) has been revised to $5.30 / share. This is a decrease of 10.86% from the prior estimate of $5.95 dated December 18, 2025.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results